Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors

被引:0
作者
Toshihiko Doi
Yusuke Onozawa
Nozomu Fuse
Takayuki Yoshino
Kentaro Yamazaki
Junichiro Watanabe
Mikhail Akimov
Matthew Robson
Narikazu Boku
Atsushi Ohtsu
机构
[1] National Cancer Center Hospital East,
[2] Shizuoka Cancer Center,undefined
[3] Novartis Pharma AG,undefined
[4] Novartis Pharma K.K.,undefined
来源
Cancer Chemotherapy and Pharmacology | 2014年 / 74卷
关键词
AUY922; Clinical trial; HSP90; Japanese; Phase I;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:629 / 636
页数:7
相关论文
共 239 条
[1]  
Banerji U(2009)Heat shock protein 90 as a drug target: some like it hot Clin Cancer Res 15 9-14
[2]  
Mahalingam D(2009)Targeting HSP90 for cancer therapy Br J Cancer 100 1523-1529
[3]  
Swords R(2006)Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive ACS Chem Biol 1 279-284
[4]  
Carew JS(2012)Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18 64-76
[5]  
Nawrocki ST(2008)The Hsp90 molecular chaperone: an open and shut case for treatment Biochem J 410 439-453
[6]  
Bhalla K(2009)The Hsp90 chaperone machinery: from structure to drug development BMB Rep 42 623-630
[7]  
Giles FJ(2010)HSP90 and its inhibitors Oncol Rep 23 1483-1492
[8]  
Chiosis G(2010)Targeting the dynamic HSP90 complex in cancer Nat Rev Cancer 10 537-549
[9]  
Neckers L(2008)4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J Med Chem 51 196-218
[10]  
Neckers L(2008)NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis Cancer Res 68 2850-2860